Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

Shilpa Medicare’s Joint Venture Oncosol (50:50 JV with Liqmeds Lifecare Limited, a Zydus group company and Koana Healthcare Limited, Shilpa Medicare group company) along with its partner Shorla Oncology announces that the USFDA has approved IMKELDI (imatinib oral solution), the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers.

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy. IMKELDI can help slow or prevent the growth of specific cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and gastrointestinal tumors (GIST).

In 2024, an estimated 9,280 people will be diagnosed with CML, over 10,000 with MDS/MPD, and up to 6,000 with GIST in the U.S. Despite the proven clinical benefits of imatinib, patient adherence can be an issue underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system.